^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MEBGEN™ BRAF Kit

    Company:
    JSR Life Sciences
    Type:
    Other Approval
    Related tests:
    Details
    Evidence

    News

    8ms
    Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer. (PubMed, Int J Clin Oncol)
    Concordance between IHC and genomic testing in assessing BRAF V600E was encouragingly high; its reliability and potentially short TAT should benefit patients, especially those with ATC.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    FoundationOne® CDx • Oncomine™ Dx Target Test • MEBGEN™ BRAF 3 Kit • MEBGEN™ BRAF Kit
    over3years
    MEBGEN BRAF Kit receives MHLW approval as companion diagnostic for use with patients with melanoma (JSR Life Sciences Press Release)
    "Medical and Biological Laboratories Co., Ltd...announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022...MEBGEN™ BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma."
    Japanese regulatory
    |
    MEBGEN™ BRAF Kit